BRIEF published on 10/15/2025 at 19:05, 3 months 20 days ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
BRIEF published on 10/15/2025 at 19:05, 3 months 20 days ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
PRESS RELEASE published on 10/15/2025 at 19:00, 3 months 20 days ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 3 months 20 days ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 3 months 27 days ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
BRIEF published on 10/09/2025 at 16:02, 3 months 27 days ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
PRESS RELEASE published on 10/09/2025 at 15:57, 3 months 27 days ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 4 months 4 days ago OSE Immunotherapeutics: Reorganization of the Board of Directors Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
BRIEF published on 09/30/2025 at 19:35, 4 months 4 days ago OSE Immunotherapeutics : Réorganisation du Conseil d'administration Biotechnologie Conseil D'administration Immunothérapie OSE Immunotherapeutics Markus Cappel
PRESS RELEASE published on 09/30/2025 at 19:30, 4 months 4 days ago Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors OSE Immunotherapeutics renews Board of Directors and elects Dr. Markus Cappel as Chairman. Shareholders vote on key appointments Board Of Directors Shareholders General Meeting OSE Immunotherapeutics Dr. Markus Cappel
Published on 02/05/2026 at 16:40, 21 minutes ago Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 1 hour 16 minutes ago American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report
Published on 02/05/2026 at 15:10, 1 hour 51 minutes ago Electric Metals (USA) Limited Announces Change of Auditor
Published on 02/05/2026 at 14:50, 2 hours 11 minutes ago High Tide Resources Announces Non-Brokered Private Placements
Published on 02/05/2026 at 14:30, 2 hours 31 minutes ago Electrovaya Announces Date for Q1-2026 Financial Results & Conference Call
Published on 02/05/2026 at 16:20, 41 minutes ago Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 02/05/2026 at 16:20, 41 minutes ago Birla Carbon Launches New Continua™ SCM Production Line in Italy
Published on 02/05/2026 at 15:56, 1 hour 5 minutes ago Original-Research: Verve Group SE (von First Berlin Equity Research GmbH): Kaufen
Published on 02/05/2026 at 15:40, 1 hour 21 minutes ago BIKE24 exceeds revenue and earnings forecast for fiscal year 2025 – strong growth in the fourth quarter
Published on 02/05/2026 at 16:04, 57 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 02/05/2026 at 16:02, 58 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
Published on 02/05/2026 at 11:30, 5 hours 31 minutes ago Déclaration nombre d'actions et droits de vote - 05.02.2026
